David Price1, Ashish Sharma, Frank Cerasoli. 1. University of Aberdeen, Foresterhill Health Centre, Department of General Practice and Primary Care, Westburn Road, Aberdeen AB25 2AY, UK. david@respiratoryresearch.org
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting anti-cholinergic for the maintenance treatment of COPD. OBJECTIVE: To review biochemical and pharmacokinetic data on tiotropium and discuss in the context of tiotropium's efficacy and safety in COPD. METHODS: Review of previously done pharmacokinetic studies performed by the manufacturer of tiotropium. Data obtained through peer-reviewed publications and regulatory websites. RESULTS/ CONCLUSIONS: The long duration of action with tiotropium is owing to prolonged, competitive binding to M(3) muscarinic receptors. Tiotropium is poorly absorbed following inhalation, which largely limits side effects. Metabolism of absorbed drug is minimal and excretion is largely through the kidneys. Tiotropium is efficacious and well tolerated by patients with COPD.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting anti-cholinergic for the maintenance treatment of COPD. OBJECTIVE: To review biochemical and pharmacokinetic data on tiotropium and discuss in the context of tiotropium's efficacy and safety in COPD. METHODS: Review of previously done pharmacokinetic studies performed by the manufacturer of tiotropium. Data obtained through peer-reviewed publications and regulatory websites. RESULTS/ CONCLUSIONS: The long duration of action with tiotropium is owing to prolonged, competitive binding to M(3) muscarinic receptors. Tiotropium is poorly absorbed following inhalation, which largely limits side effects. Metabolism of absorbed drug is minimal and excretion is largely through the kidneys. Tiotropium is efficacious and well tolerated by patients with COPD.
Authors: Stephen T Horhota; Jan A van Noord; Cynthia B Verkleij; Loek J Bour; Ashish Sharma; Michael Trunk; Piet J G Cornelissen Journal: AAPS J Date: 2015-03-21 Impact factor: 4.009
Authors: J M Hohlfeld; A Sharma; J A van Noord; P J G Cornelissen; E Derom; L Towse; V Peterkin; B Disse Journal: J Clin Pharmacol Date: 2013-11-27 Impact factor: 3.126